Long non-coding RNA ANRIL promotes tumorgenesis through regulation of FGFR1 expression by sponging miR-125a-3p in head and neck squamous cell carcinoma

ANRIL (CDKN2B antisense RNA 1, CDKN2B-AS1) is involved in the progression of various cancers. However, its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. In this study, we found that ANRIL expression was upregulated in HNSCC and correlated with tumor progression. Further func...

Full description

Saved in:
Bibliographic Details
Published inAmerican journal of cancer research Vol. 8; no. 11; pp. 2296 - 2310
Main Authors Zhang, Li-Ming, Ju, Hou-Yu, Wu, Yun-Teng, Guo, Wei, Mao, Lu, Ma, Hai-Long, Xia, Wei-Ya, Hu, Jing-Zhou, Ren, Guo-Xin
Format Journal Article
LanguageEnglish
Published United States e-Century Publishing Corporation 01.01.2018
Subjects
Original
ANRIL
Head and neck squamous cell carcinoma
proliferation
miR-125a-3p
FGFR1
Online AccessGet full text

Cover

More Information
Summary:ANRIL (CDKN2B antisense RNA 1, CDKN2B-AS1) is involved in the progression of various cancers. However, its role in head and neck squamous cell carcinoma (HNSCC) remains unclear. In this study, we found that ANRIL expression was upregulated in HNSCC and correlated with tumor progression. Further functional analysis showed that knockdown of ANRIL significantly inhibited proliferation in vivo and in vitro. ANRIL functioned as a ceRNA (competing endogenous RNAs) for miR-125a-3p and upregulated FGFR1 (fibroblast growth factor receptor-1), which could promote tumor growth. Moreover, we confirmed that ANRIL promoted HNSCC activity via FGFR1 with a FGFR1 inhibitor in vivo and in vitro. Thus, it could be concluded that ANRIL promoted the progression of HNSCC via miR-125a-3p/FGFR1/MAPK signaling, which might provide a new target for the diagnosis and treatment of HNSCC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Co-first authors.
ISSN:2156-6976
2156-6976